Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Blood

• Publication date

  2012-08-02

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2012-03-412981PMID 22573403
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

  2012cited by this paper
• A Modified Method for Whole Exome Resequencing from Minimal Amounts of Starting DNA

  2012cited by this paper
• Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma

  2012cited by this paper
• Clonal evolution in cancer

  2012cited by this paper
• Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing

  2011cited by this paper
• NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.

  2011cited by this paper
• Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma.

  2011cited by this paper
• A framework for variation discovery and genotyping using next-generation DNA sequencing data

  2011cited by this paper
• Tumour evolution inferred by single-cell sequencing

  2011cited by this paper
• Initial genome sequencing and analysis of multiple myeloma

  2011cited by this paper
• A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial

  2011cited by this paper
• Genetic variegation of clonal architecture and propagating cells in leukaemia

  2011cited by this paper
• Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival

  2011cited by this paper
• The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells

  2011cited by this paper
• Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations.

  2010cited by this paper
• A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value.

  2010cited by this paper
• The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance

  2010cited by this paper
• MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites

  2010cited by this paper
• ROCK: a breast cancer functional genomics resource

  2010cited by this paper
• ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data

  2010cited by this paper
• Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome

  2010cited by this paper
• A monoclonal gammopathy precedes multiple myeloma in most patients.

  2009cited by this paper
• Deletions of CDKN2C in Multiple Myeloma: Biological and Clinical Implications

  2008cited by this paper
• Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia

  2008cited by this paper
• The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor.

  2008cited by this paper
• Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing

  2008cited by this paper
• Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia.

  2008cited by this paper
• Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

  2007cited by this paper
• Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

  2007cited by this paper
• Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma.

  2007cited by this paper
• Use of single nucleotide polymorphism-based mapping arrays to detect copy number changes and loss of heterozygosity in multiple myeloma.

  2006cited by this paper
• High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients.

  2006influential reference
• Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma.

  2006cited by this paper
• A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia.

  2005cited by this paper
• Molecular Pathogenesis of MLL-Associated Leukemias

  2005cited by this paper
• Molecular pathogenesis and a consequent classification of multiple myeloma.

  2005cited by this paper
• Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis.

  2003cited by this paper
• In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.

  2003influential reference
• Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias.

  1993cited by this paper

• Multiple Myeloma Insights from Single-Cell Analysis: Clonal Evolution, the Microenvironment, Therapy Evasion, and Clinical Implications

  2025cites this paper
• RUNX1 expression dynamics in plasma cell differentiation and pathogenesis of multiple myeloma

  2025cites this paper
• Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

  2025cites this paper
• Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma

  2025cites this paper
• Identification of Genetic Predisposition to Sjogren's Syndrome by Whole Exome Sequencing

  2024cites this paper
• Heterogeneidad molecular en mieloma múltiple

  2024cites this paper
• Dissecting the Puzzling Roles of FAM46C: A Multifaceted Pan-Cancer Tumour Suppressor with Increasing Clinical Relevance

  2024cites this paper
• Concerted antibody and antigen discovery by differential whole-cell phage display selections and multi-omic target deconvolution.

  2023cites this paper
• Phenotype-structured model of intra-clonal heterogeneity and drug resistance in multiple myeloma.

  2023cites this paper
• Single-cell technologies in multiple myeloma: new insights into disease pathogenesis and translational implications

  2023cites this paper
• Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma

  2023cites this paper
• Effect of MAPK activation via mutations in NRAS, KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma

  2023cites this paper
• Single-Cell Transcriptomes Combining with Consecutive Genomics Reveal Clonal Evolution and Gene Regulatory Networks in Relapsed and Refractory Multiple Myeloma

  2022cites this paper
• Modulation of DNA Damage Response by SAM and HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase (SAMHD1) Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types

  2022cites this paper
• Loss of ribonuclease DIS3 hampers genome integrity in myeloma by disrupting DNA:RNA hybrid metabolism

  2022cites this paper
• Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance

  2022cites this paper
• Liquid Biopsy-Derived DNA Sources as Tools for Comprehensive Mutation Profiling in Multiple Myeloma: A Comparative Study

  2022cites this paper
• Correlation of plasma cell assessment by phenotypic methods and molecular profiles by NGS in patients with plasma cell dyscrasias

  2022influential citation
• A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics

  2021cites this paper
• SAMHD1 in cancer: curse or cure?

  2021cites this paper
• Roadmap to cure multiple myeloma.

  2021cites this paper
• Targeting UCHL1 Induces Cell Cycle Arrest in High-Risk Multiple Myeloma with t(4;14)

  2021cites this paper
• Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma

  2021cites this paper
• Evaluation of measurable residual disease in multiple myeloma by multiparametric flow cytometry: Current paradigm, guidelines, and future applications

  2021cites this paper
• Genome Instability in Multiple Myeloma: Facts and Factors

  2021cites this paper
• Epidemiology, genetics and treatment of multiple myeloma and precursor diseases

  2021cites this paper
• Smoldering multiple myeloma - Past, present, and future.

  2021cites this paper
• Genomic Instability in Multiple Myeloma.

  2020cites this paper
• Targeted Therapy With Immunoconjugates for Multiple Myeloma

  2020cites this paper
• Aberrant BUB1 Overexpression Promotes Mitotic Segregation Errors and Chromosomal Instability in Multiple Myeloma

  2020cites this paper
• Navigating the Role of CD1d/Invariant Natural Killer T-cell/Glycolipid Immune Axis in Multiple Myeloma Evolution: Therapeutic Implications.

  2020cites this paper
• Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma.

  2020cites this paper
• Single cell RNA-seq data and bulk gene profiles reveal a novel signature of disease progression in multiple myeloma

  2020cites this paper
• Biological and Translational Considerations regarding the Recent Therapeutic Successes and Upcoming Challenges for Multiple Myeloma.

  2020cites this paper
• The Eukaryotic RNA Exosome: Methods and Protocols

  2020cites this paper
• Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?

  2020influential citation
• An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics

  2020cites this paper
• RNA Exosomes and Their Cofactors.

  2020cites this paper
• Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractor

  2020cites this paper
• A highly heterogeneous mutational pattern in POEMS syndrome

  2020cites this paper
• Analysis of the TCGA Dataset Reveals that Subsites of Laryngeal Squamous Cell Carcinoma Are Molecularly Distinct

  2020cites this paper
• GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice

  2020cites this paper
• From the Clinic to the Bench and Back Again in One Dog Year: How a Cross-Species Pipeline to Identify New Treatments for Sarcoma Illuminates the Path Forward in Precision Medicine

  2020cites this paper
• Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation

  2020cites this paper
• Multiple Myeloma: Methods and Protocols

  2020influential citation
• Frequent loss of BTG1 activity and impaired interactions with the Caf1 subunit of the Ccr4–Not deadenylase in non-Hodgkin lymphoma

  2020cites this paper
• Molecular basis of clonal evolution in multiple myeloma

  2020cites this paper
• Latest perspectives on glucocorticoid-induced apoptosis and resistance in lymphoid malignancies.

  2020cites this paper
• Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines

  2020influential citation
• Deep sequencing as an approach to understanding the complexity and improving the treatment of multiple myeloma

  2020cites this paper
• The RNA Exosome and Human Disease.

  2020cites this paper
• A decade with whole exome sequencing in haematology

  2020cites this paper
• The DNA methylation landscape of multiple myeloma shows extensive inter- and intrapatient heterogeneity that fuels transcriptomic variability

  2020cites this paper
• Post-transcriptional control of cellular differentiation by the RNA exosome complex

  2020cites this paper
• Structural and Functional Analyses of the FAM46C/Plk4 Complex.

  2020cites this paper
• A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones?

  2019cites this paper
• Title Endogenous APOBEC 3 B Overexpression ConstitutivelyGenerates DNA Substitutions and Deletions in Myeloma Cells

  2019cites this paper
• The Implication of mRNA Degradation Disorders on Human DISease: Focus on DIS3 and DIS3-Like Enzymes.

  2019cites this paper
• High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment

  2019cites this paper
• 1 High-Risk Multiple Myeloma : Integrated Clinical 2 and Omics Approach Dissects the Neoplastic Clone 3 and the Tumor Microenvironment 4

  2019cites this paper
• Unfavourable biological prognostic factors in Multiple Myeloma

  2019cites this paper
• Monoclonal Immunoglobulin

  2019cites this paper
• Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma.

  2019cites this paper
• Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells

  2019cites this paper
• Mutations In Thirty Hotspot Genes In Newly Diagnosed Chinese Multiple Myeloma Patients

  2019influential citation
• Clonal evolution in myeloma: a narrow road to remission

  2019cites this paper
• Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance

  2019cites this paper
• Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma

  2019cites this paper
• Kinome expression profiling to target new therapeutic avenues in multiple myeloma

  2019cites this paper
• From the clinic to the bench and back again in one dog year: identifying new treatments for sarcoma using a cross-species personalized medicine pipeline

  2019cites this paper
• Defective modulation of LINE-1 retrotransposition by cancer-associated SAMHD1 mutants.

  2019cites this paper
• Mutations In Thirty Hotspot Genes In Newly Diagnosed Chinese Multiple Myeloma Patients

  2019influential citation
• NSD 2 overexpression drives clustered chromatin and transcriptional changes in insulated domains

  2019cites this paper
• NSD2 overexpression drives clustered chromatin and transcriptional changes in a subset of insulated domains

  2019cites this paper
• Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma

  2019cites this paper
• Lower number of 5-hydroxymethylcytosine-expressing cells in plasma cell myeloma than in reactive plasma cell hyperplasia: a useful immunohistochemical approach for identification of neoplastic plasma cells.

  2019cites this paper
• Purine-Metabolising Enzymes and Apoptosis in Cancer

  2019cites this paper
• Multiple Myeloma Summit In this review : Real-world MM outcomes in Australasia : optimising treatment –

  2018cites this paper
• DIS3 isoforms vary in their endoribonuclease activity and are differentially expressed within haematological cancers

  2018cites this paper
• Characterization and use of the novel human multiple myeloma cell line MC-B11/14 to study biological consequences of CRISPR-mediated loss of immunoglobulin A heavy chain.

  2018cites this paper
• Prevalence and Clinicopathologic Significance of BRAF V600E Mutation in Chinese Multiple Myeloma Patients

  2018cites this paper
• Nuclear mRNA Surveillance Mechanisms: Function and Links to Human Disease.

  2018cites this paper
• Whole Exome Sequencing in Multiple Myeloma to Identify Somatic Single Nucleotide Variants and Key Translocations Involving Immunoglobulin Loci and MYC.

  2018cites this paper
• Genetic alterations crossing the borders of distinct hematopoetic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology.

  2018cites this paper
• MOLECULAR HETEROGENEITY OF MULTIPLE MYELOMA: THE BIOLOGICAL AND CLINICAL RELEVANCE OF NOVEL GENE MUTATIONS BY NEXT GENERATION SEQUENCING

  2018cites this paper
• Therapeutic Targets and Signaling Pathways for Diagnosis of Myeloma

  2018cites this paper
• 1 Identification of Novel Mutational Drivers Reveals Oncogene Dependencies In Multiple Myeloma . Short title : Oncogene dependencies in myeloma

  2018cites this paper
• Kinase domain activation through gene rearrangement in multiple myeloma

  2018cites this paper
• Evolution of Cancer Progression in the Context of Darwinism

  2018cites this paper
• Treatment of Transplant Eligible Patients with Multiple Myeloma

  2018cites this paper
• Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms

  2018cites this paper
• Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma.

  2018influential citation
• Genomic patterns of progression in smoldering multiple myeloma

  2018cites this paper
• Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells

  2018cites this paper
• Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma.

  2018cites this paper
• Mutational Intratumor Heterogeneity is a Complex and Early Event in the Development of Adult T-cell Leukemia/Lymphoma

  2018cites this paper
• Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.

  2018cites this paper
• Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma

  2018cites this paper
• Multiple myeloma clonal evolution in homogeneously treated patients

  2018cites this paper
• A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

  2018cites this paper